Summary
Tiotropium Bromide has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Asthma would be drug repurposing rather than first-in-human development. This does not mean it is approved for Asthma. ClinicalTrials.gov lists 8 registered trials linking Tiotropium Bromide to Asthma: 1 is currently recruiting; 7 have completed. The most advanced is Phase 4 (NCT02682862). The largest enrolment is 1032 participants (NCT01172821). Registration activity spans 2008 to 2024. The literature layer holds 10 publications for this pair: 3 Cochrane reviews, 2 systematic reviews and 5 clinical trial publications. Publication years run from 2004 to 2021. Because at least one synthesis-level source exists (systematic review, meta-analysis or Cochrane review), this pair has been assessed beyond single studies, although the synthesis may concern a different indication.
The RepurpOS disease-intelligence file for Asthma ranks 642 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: 26% of childhood-onset asthma in clinical remission by adulthood; <20% adult-onset achieves sustained remission; 65% long-term remission in mild-moderate vs 16% in severe.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 79.5 (trials 29.5, literature 30.0, tier 15, approved bonus 5.0) |
| Registered trials | 8 total: 1 recruiting, 0 active / not yet recruiting, 7 completed, 0 other |
| Linked publications | 10 (5 clinical trial publications, 3 Cochrane reviews, 2 systematic reviews) |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | Not recorded |
| Data sources | Open Targets, ChEMBL |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT02682862 | Ultra-long Acting Bronchodilator Therapy in Smoking Asthmatics 2016 | completed | Phase 4 | 17 |
| NCT01316380 | Efficacy and Safety of 2 Doses of Tiotropium Via Respimat in Adult Patients With Mild Persistent Asthma 2011 | completed | Phase 3 | 465 |
| NCT01172821 | Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II 2010 | completed | Phase 3 | 1,032 |
| NCT01152450 | A Randomised, Double- Blind, Placebo Controlled, Cross-over Efficacy and Safety Comparison of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for Four Weeks in Patients With Moderate Persistent Asthma 2010 | completed | Phase 2 | 94 |
| NCT01634113 | Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo in 1 to 5 Year Old Patients With Persistent Asthma 2012 | completed | Phase 2 | 102 |
| NCT00557700 | Study to Investigate the Effect of Inhaled Tiotropium Bromide on Neurokinin-A Induced Bronchoconstriction in Patients With Mild-to-moderate Asthma 2008 | completed | Phase 2 | 15 |
| NCT02489981 | Specific Use-result Surveillance of Spiriva Respimat in Asthmatics 2015 | completed | Not applicable | 359 |
| NCT06609941 | Additive Effects of Alternative Nostril Breathing with Pharmacological Management on Dyspnea and Control Pause in Patients with Bronchial Asthma 2024 | recruiting | Not applicable | 32 |
Published literature
- Systematic review Tiotropium in the management of paediatric and adolescent asthma: Systematic reviewSunther M, Marchon K, Gupta A · Paediatric respiratory reviews · 2021 · PMID 33243704
- Clinical trial publication Inhaled Glucocorticoid with or without Tiotropium Bromide for Asthma-Chronic Obstructive Pulmonary Disease Overlap SyndromeXu H, Lu X · Journal of the College of Physicians and Surgeons--Pakistan : JCPSP · 2019 · PMID 30823952
- Clinical trial publication Therapeutic Effects of a Long-Acting Cholinergic Receptor Blocker, Tiotropium Bromide, on AsthmaZhang L, Huang G, Jin L et al. · Medical science monitor : international medical journal of experimental and clinical research · 2018 · PMID 29446377
- Systematic review Efficacy and safety of tiotropium in school-age children with moderate-to-severe symptomatic asthma: A systematic reviewRodrigo GJ, Neffen H · Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2017 · PMID 28692145
- Cochrane review Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthmaKew KM, Dahri K · The Cochrane database of systematic reviews · 2016 · PMID 26798035
- Cochrane review Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults with asthmaEvans DJ, Kew KM, Anderson DE et al. · The Cochrane database of systematic reviews · 2015 · PMID 26196545
- Clinical trial publication Predictors of response to tiotropium versus salmeterol in asthmatic adultsPeters SP, Bleecker ER, Kunselman SJ et al. · The Journal of allergy and clinical immunology · 2013 · PMID 24084072
- Clinical trial publication Tiotropium bromide step-up therapy for adults with uncontrolled asthmaPeters SP, Kunselman SJ, Icitovic N et al. · The New England journal of medicine · 2010 · PMID 20979471
- Clinical trial publication Glycopyrrolate causes prolonged bronchoprotection and bronchodilatation in patients with asthmaHansel TT, Neighbour H, Erin EM et al. · Chest · 2005 · PMID 16236844
- Cochrane review Anticholinergic agents for chronic asthma in adultsWestby M, Benson M, Gibson P · The Cochrane database of systematic reviews · 2004 · PMID 15266477
Mechanism and notes
No mechanism of action is recorded for this pair in the source databases.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in Open Targets and ChEMBL. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Tiotropium Bromide approved for Asthma?
Tiotropium Bromide has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Asthma would be drug repurposing rather than first-in-human development. This does not mean it is approved for Asthma. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Tiotropium Bromide in clinical trials for Asthma?
ClinicalTrials.gov lists 8 registered trials linking Tiotropium Bromide to Asthma: 1 is currently recruiting; 7 have completed. The most advanced is Phase 4 (NCT02682862). The largest enrolment is 1032 participants (NCT01172821). Registration activity spans 2008 to 2024.
What does the evidence show for Tiotropium Bromide in Asthma?
Tiotropium Bromide has both completed registered trials and synthesis-level publications linked to Asthma. That is the strongest profile in this database, but the summaries here do not extract effect sizes, so read the linked reviews for direction and magnitude of benefit. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in Open Targets and ChEMBL. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.